Sydney Lepkin

custom prepare the version for you that you are not allergic to because you obviously need that.

And it's a crucial part of health care.

They're generally not supposed to make what are called, quote, essentially copies.

And I'm using air quotes for those who can't see me.

Essentially copies of existing commercial brand name drugs.

But there's an exception.

The exception is when that brand name drug is in shortage.

Then the compounding pharmacies can pitch in.

Now, these GLP-1s that we've been talking about their popularity, in fact, they were so, so, so popular that the drug companies didn't make enough supply.

And all of a sudden, you know, compounders were like, well, we can actually do this for cheaper than the list price for Wagovi is like $1,400 a month.

So all of a sudden, people could get it for cheaper.

Telehealths were helping connect them with physicians.

And that's sort of where this boom is coming from.

Now, the shortages have ended.

The companies, it took them a couple of years to catch up on the manufacturing side, but the shortages have ended.

And the thought was that the compounding would also end.

But

What is now happening is a lot of companies are saying, well, what we'll do is we will make you a custom version of this drug.

And then they think that there are at least some that I've spoken to have said, you know, then I think that we're working within the parameters of the law.

And there's some definite debate about whether that's true.